Overview

Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

Primary: - To evaluate the efficacy of two regimens of irbesartan in patients responding but not normalized at 6 weeks of treatment (schema N°1: maintenance 150 mg/day, schema n°2: 300 mg/day for 6 more weeks) Secondary: - To evaluate the percentage of patients with DBP < 90 mmHg at 6 and 12 weeks - To evaluate the percentage of patients with SBP < 140 mmHg at 6 and 12 weeks - To evaluate rate of adverse events during the study

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Collaborator:

Bristol-Myers Squibb

Treatments:

Irbesartan